NCT00371059

Memantine for Agitation in Dementia

Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 153 (actual)
• Sponsor: East Kent Hospitals University NHS Foundation Trust · Other Government
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks

Detailed description

Agitation is a cause of morbidity and mortality in Alzheimer's due to distress and use of medication with side effects. Memantine has beed shown to be associated with less agitation and a recent study by forrest pharmaceuticals failed to recruit. We will perform a 12 week rct in 164 patients to test this hypothesis in a locality with no competing studies and in a clinical setting where the drug is not often used. We will compare with placebo and also use a rescue protocol derived from international best practice.

Conditions

• DEMENTIA

Interventions

Type	Name	Description
DRUG	Memantine	Memantine 10mg BD
DRUG	Placebo	Placebo 10 mgs BD

Timeline

• Start date: 2007-09-01
• Primary completion: 2009-06-01
• Completion: 2009-09-01
• First posted: 2006-09-01
• Last updated: 2022-04-06

Locations

2 sites across 1 country: United Kingdom